Australië - Engels - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - everolimus, quantity: 2.5 mg - tablet - excipient ingredients: magnesium stearate; lactose; lactose monohydrate; hypromellose; butylated hydroxytoluene; crospovidone - afinitor is indicated for the treatment of:,? postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ? progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin. ? progressive, unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours (net) of gastrointestinal or lung origin in adults. ? advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib. ? subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection. ? patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery. afinitor is indicated for the: ? treatment of postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ? treatment of progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin. ? treatment of progressive, unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours (net) of gastrointestinal or lung origin in adults. ? treatment of advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib. ? treatment of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection. ? treatment of patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery. ? adjunctive treatment of patients aged 2 years and older with tsc and associated refractory seizures.

Zuid-Afrika - Engels - South African Health Products Regulatory Authority (SAHPRA)

austell pharmaceuticals (pty) ltd - tablet - see ingredients - each tablet contains rivaroxaban 10,0 mg

Zuid-Afrika - Engels - South African Health Products Regulatory Authority (SAHPRA)

austell pharmaceuticals (pty) ltd - tablet - see ingredients - each tablet contains rivaroxaban 10,0 mg

Zuid-Afrika - Engels - South African Health Products Regulatory Authority (SAHPRA)

teva pharmaceuticals (pty) ltd - tablet - see ingredients - each tablet contains rivaroxaban 10,0 mg

Zuid-Afrika - Engels - South African Health Products Regulatory Authority (SAHPRA)

pharma dynamics (pty) ltd - tablet - 10,0 mg - each tablet contains rivaroxaban 10,0 mg

Australië - Engels - Department of Health (Therapeutic Goods Administration)

correvio australia pty ltd - tirofiban hydrochloride -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - clopidogrel hydrogen sulfate -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - clopidogrel hydrogen sulfate; clopidogrel (as hydrogen sulfate) -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - clopidogrel hydrogen sulfate -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - clopidogrel hydrogen sulfate -